| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/13/2023 | 559.8% | Cantor Fitzgerald | → $5 | Reiterates | Overweight → Overweight |
| 02/08/2023 | 823.73% | SVB Leerink | $9 → $7 | Maintains | Outperform |
| 06/02/2022 | 559.8% | Cantor Fitzgerald | → $5 | Initiates Coverage On | → Overweight |
| 05/05/2022 | 97.94% | Piper Sandler | $25 → $1.5 | Downgrades | Overweight → Neutral |
| 05/04/2022 | 1087.65% | SVB Leerink | $22 → $9 | Maintains | Outperform |
| 01/06/2022 | 2803.14% | SVB Leerink | $32 → $22 | Maintains | Outperform |
| 07/02/2021 | 3462.95% | CICC | → $27 | Initiates Coverage On | → Outperform |
| 04/13/2021 | 3462.95% | Jefferies | → $27 | Initiates Coverage On | → Buy |
| 04/13/2021 | 4122.75% | SVB Leerink | → $32 | Initiates Coverage On | → Outperform |
What is the target price for Connect Biopharma Hldgs (CNTB)?
The latest price target for Connect Biopharma Hldgs (NASDAQ: CNTB) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $5.00 expecting CNTB to rise to within 12 months (a possible 559.80% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Connect Biopharma Hldgs (CNTB)?
The latest analyst rating for Connect Biopharma Hldgs (NASDAQ: CNTB) was provided by Cantor Fitzgerald, and Connect Biopharma Hldgs reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Connect Biopharma Hldgs (CNTB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Connect Biopharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Connect Biopharma Hldgs was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.
Is the Analyst Rating Connect Biopharma Hldgs (CNTB) correct?
While ratings are subjective and will change, the latest Connect Biopharma Hldgs (CNTB) rating was a reiterated with a price target of $0.00 to $5.00. The current price Connect Biopharma Hldgs (CNTB) is trading at is $0.76, which is within the analyst's predicted range.
